Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction

Coronary Artery Disease

Volumn 24, Issue 6, 2013, Pages 487-492

  Løgstrup, Brian B ^a   Høfsten, Dan E ^a   Christophersen, Thomas B ^a   Møller, Jacob E ^b   Bjerre, Mette ^c,d   Flyvbjerg, Allan ^c,d   Bøtker, Hans E ^c,d   Egstrup, Kenneth ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b University of Copenhagen   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

acute myocardial infarction; coronary flow reserve; echocardiography; microcirculation; osteoprotegerin

Indexed keywords

DOBUTAMINE; OSTEOPROTEGERIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY FLOW RESERVE; DIASTOLE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MICROVASCULARIZATION; NON INVASIVE PROCEDURE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STRESS ECHOCARDIOGRAPHY;

EID: 84881541946     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328363242e     Document Type: Article

References (30)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
2. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521:180-184.
3. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha v beta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275:20959-20962.
4. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010; 6:94-101.
5. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-2180.
6. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44:1970-1976.
7. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17:262-270.
8. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49: 1392-1398.
9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
10. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23:489-494.
11. Moe SM, Reslerova M, Ketteler M, O'neill K, Duan D, Koczman J, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67:2295-2304.
12. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64:652-658.
13. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88:1024-1028.
14. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857.
15. Chantler PD, Lakatta EG, Najjar SS. Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol 2008; 105:1342-1351.
16. Smart SC, Sawada S, Ryan T, Segar D, Atherton L, Berkovitz K, et al. Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Circulation 1993; 88:405-415.
17. Logstrup BB, Hofsten DE, Christophersen TB, Moller JE, Botker HE, Pellikka PA, et al. Association between coronary flow reserve, left ventricular systolic function, and myocardial viability in acute myocardial infarction. Eur J Echocardiogr 2010; 11:665-670.
18. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154:75-81.
19. Ren MY, Sui SJ, Zhang Y, Xu FY, Xu XQ, Zhao JJ, et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 2008; 63:615-622.
20. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-1194.
21. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso study. J Thromb Haemost 2011; 9:638-644.
22. Yang Q, Lu S, Chen Y, Song X, Jin Z, Yuan F, et al. Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. Clin Cardiol 2011; 34:447-453.
23. Erkol A, Pala S, Kirma C, Oduncu V, Dundar C, Izgi A, et al. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 2011; 107:857-862.
24. Andersen GO, Knudsen EC, Aukrust P, Yndestad A, Oie E, Muller C, et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011; 97:460-465.
25. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111:2461-2468.
26. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29:1664-1666.
27. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract 2007; 76:199-206.
28. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004; 15:2834-2841.
29. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van DE, Lubberink M, et al. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 2011; 10:67.
30. Segers P, Stergiopulos N, Westerhof N. Relation of effective arterial elastance to arterial system properties. Am J Physiol Heart Circ Physiol 2002; 282:H1041-H1046.